DOKing tumor progression in ccRCC

Affiliations

¹ Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
² Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
³ First University Department of Respiratory Medicine, 'Sotiria' Chest Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

Christos Adamopoulos et al. J Cancer. 2024.

. 2024 Oct 15;15(19):6416-6417.

doi: 10.7150/jca.104784. eCollection 2024.

¹ Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
² Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
³ First University Department of Respiratory Medicine, 'Sotiria' Chest Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

No abstract available

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

1. Xie W, Shu B, Zhang Y. et al. DOK1 facilitates the advancement of ccRCC. J Cancer. 2024;15(19):6213–6222. doi:10.7150/jca.104375. - PMC - PubMed
1. Choueiri TK, Motzer RJ. Systemic Therapy for Metastatic Renal-Cell Carcinoma. N Engl J Med. 2017;376:354–66. - PubMed
1. Vish KJ, Stiegler AL, Boggon TJ. Diverse p120RasGAP interactions with doubly phosphorylated partners EphB4, p190RhoGAP, and Dok1. J Biol Chem. 2023;299:105098. - PMC - PubMed
1. Gutting T, Merkel A, Fink DJ. et al. Expression of the EGFR-RAS Inhibitory Proteins DOK1 and MTMR7 and its Significance in Colorectal Adenoma and Adenoma Recurrence. J Gastrointestin Liver Dis. 2021;3:446–55. - PubMed
1. Miah S, Goel RK, Dai C, BRK targets Dok1 for ubiquitin-mediated proteasomal degradation to promote cell proliferation and migration PLoS One. 2014; 9: e87684. - PMC - PubMed